Across TCGA pan-cancer cohorts, TMLHE mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMLHE data layer compared with 21 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMLHE mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMLHE expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
PDAC, LUAD, and LSCC are the cancer types where TMLHE mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.